I am presenting a poster on my recent work at two upcoming conferences: Cambridge Lymphoma Biology International Symposium (14-15th September 2026) and the 7th NF-kB International Congress in Barcelona (6-9th October 2026). Travel bursaries to attend these events have been kindly provided by the UK CLL Forum and by Brighton and Sussex Medical School.

Supplementary Methods

Experimental Methods

• Spectral flow cytometry data was collected using the panel below and fingerprints were generated using Julia 1.8.5 as described by Jayawant et al., 2023 and Vareli et al., 2025 (see Publications for further details). 

• Nuclear ELISAs were performed using ActiveMotif TransAm NF-κB Family Kit, using nuclear extracts prepared with the ActiveMotif Nuclear Extract Kit. 

• Fractionation was validated using tubulin and lamin western blots (not shown).

• RNA sequencing was performed by ActiveMotif. QC analysis was performed in-house and is shown below. All analysis was performed using R 4.6.0.

Computational Methods

• Ordinary differential equations were solved using Julia 1.8.5, to calculate the relative abundances of NF-κB subunits.

• Parameter optimisation was performed using a combined simulated annealing and particle swarm optimisation (PSO) approach. 

• Initially, a 39-parameter space was explored with bounds of 0.01 and 10 (10 conditions; three NF-κB synthesis parameters per condition; plus nine global coupling parameters between NF-κB and BCL2 family members). 

• This provided a good fit, but in order to further refine the model a second round of PSO was performed to optimise MCL1 degradation (with the 39 "best" parameters from the previous optimisation fixed). 

• This provided an excellent fit with minimal error between the z-scores from the experimental data and those from the simulated cells.

• 1000 cells were simulated per conditions (10000 simulations in total).